Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy

Detalles Bibliográficos
Autores principales: Gadhoum, S Z, Madhoun, N Y, Abuelela, A F, Merzaban, J S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155032/
https://www.ncbi.nlm.nih.gov/pubmed/27499140
http://dx.doi.org/10.1038/leu.2016.221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155032/
https://www.ncbi.nlm.nih.gov/pubmed/27499140
http://dx.doi.org/10.1038/leu.2016.221

Ejemplares similares